BR112013032232A2 - método de caracterização de câncer através do uso de biomarcador de ácido nucleico - Google Patents
método de caracterização de câncer através do uso de biomarcador de ácido nucleicoInfo
- Publication number
- BR112013032232A2 BR112013032232A2 BR112013032232A BR112013032232A BR112013032232A2 BR 112013032232 A2 BR112013032232 A2 BR 112013032232A2 BR 112013032232 A BR112013032232 A BR 112013032232A BR 112013032232 A BR112013032232 A BR 112013032232A BR 112013032232 A2 BR112013032232 A2 BR 112013032232A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- biomarkers
- stages
- condition
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Abstract
biomarker compositions and methods abstract biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. these include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes. tradução: resumo patente de invenção: "biomarcadores de circulação para cân-cer". biomarcadores podem ser avaliados para métodos de diagnós-tico, relacionados à terapia ou prognóstico para identificar fenótipos, tal como uma condição ou doença, ou o estágio ou progressão de uma doença, selecionar regimes de tratamento candidatos para doenças, condições, es-tágios de doença e estágios de uma condição e determinar eficácia do tra-tamento. biomarcadores de circulação de um fluido corporal podem ser usa-dos no traçado do perfil de estados fisiológicos ou determinação de fenótipos. esses incluem ácidos nucléicos, proteína e estruturas de circulação tais como vesículas e complexos de ácido nucleico-proteína.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161497895P | 2011-06-16 | 2011-06-16 | |
US201161499138P | 2011-06-20 | 2011-06-20 | |
US201161501680P | 2011-06-27 | 2011-06-27 | |
US201161506019P | 2011-07-08 | 2011-07-08 | |
US201161506606P | 2011-07-11 | 2011-07-11 | |
US201161506598P | 2011-07-11 | 2011-07-11 | |
US201161507989P | 2011-07-14 | 2011-07-14 | |
US201161511455P | 2011-07-25 | 2011-07-25 | |
US201161523763P | 2011-08-15 | 2011-08-15 | |
US201161526623P | 2011-08-23 | 2011-08-23 | |
PCT/US2012/042519 WO2012174282A2 (en) | 2011-06-16 | 2012-06-14 | Biomarker compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013032232A2 true BR112013032232A2 (pt) | 2016-09-20 |
Family
ID=47357742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013032232A BR112013032232A2 (pt) | 2011-06-16 | 2012-06-14 | método de caracterização de câncer através do uso de biomarcador de ácido nucleico |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140220580A1 (pt) |
EP (1) | EP2721179A4 (pt) |
JP (1) | JP2014519340A (pt) |
KR (1) | KR20140072014A (pt) |
CN (1) | CN103797131A (pt) |
AU (1) | AU2012271516A1 (pt) |
BR (1) | BR112013032232A2 (pt) |
CA (1) | CA2839530A1 (pt) |
WO (1) | WO2012174282A2 (pt) |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102089444A (zh) | 2008-05-14 | 2011-06-08 | 德玛泰克国际公司 | 利用核酸分析方法来诊断黑素瘤和太阳能雀斑 |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
EP2524055A4 (en) | 2010-01-11 | 2013-06-05 | Genomic Health Inc | METHOD FOR THE USE OF GENE EXPRESSION FOR DETERMINING THE PROBABILITY OF CLINICAL EXERCISE OF KIDNEY CANCER |
EP2556172A4 (en) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASES |
WO2011131354A1 (en) * | 2010-04-20 | 2011-10-27 | Febit Holding Gmbh | Complex mirna sets as novel biomarkers for an acute coronary syndrome |
US9417249B2 (en) * | 2011-09-16 | 2016-08-16 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pre-term birth |
WO2013049680A1 (en) * | 2011-09-28 | 2013-04-04 | The General Hospital Corporation | Cadherins as cancer biomarkers |
US9447471B2 (en) * | 2011-12-29 | 2016-09-20 | Quest Diagnostics Investments Incorporated | Microrna profiling for diagnosis of dysplastic nevi and melanoma |
US9275334B2 (en) * | 2012-04-06 | 2016-03-01 | Applied Materials, Inc. | Increasing signal to noise ratio for creation of generalized and robust prediction models |
JP2015517813A (ja) * | 2012-05-28 | 2015-06-25 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング/マクギル・ユニヴァーシティ | 炎症を可能にするポリペプチドおよびその使用 |
US10919883B2 (en) * | 2012-08-09 | 2021-02-16 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US10433740B2 (en) | 2012-09-12 | 2019-10-08 | Heartflow, Inc. | Systems and methods for estimating ischemia and blood flow characteristics from vessel geometry and physiology |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
CA2928520C (en) | 2012-10-23 | 2023-03-14 | Caris Life Sciences Switzerland Holdings, S.A.R.L. | Aptamers and uses thereof |
CA2895847C (en) | 2012-12-19 | 2019-01-08 | Caris Science, Inc. | Compositions and methods for aptamer screening |
US20160230227A1 (en) * | 2012-12-21 | 2016-08-11 | The New York Stem Cell Foundation | Methods of treating alzheimer's disease |
US10928402B2 (en) | 2012-12-28 | 2021-02-23 | Nx Prenatal Inc. | Treatment of spontaneous preterm birth |
US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
CN105026911B (zh) * | 2013-01-03 | 2019-01-22 | 外来体诊断公司 | 用于分离微囊泡的方法 |
US10280463B2 (en) | 2013-02-06 | 2019-05-07 | Wake Forest University Health Sciences | Identification of unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis |
ES2828510T3 (es) * | 2013-02-15 | 2021-05-26 | Univ Nat Corp Tokyo Medical & Dental | Agente terapéutico para tratar un cáncer en el que NRF2 está estabilizado |
US20160007900A1 (en) * | 2013-03-01 | 2016-01-14 | The Regents Of The University Of California | Point-of-Care Device for Monitoring Renal Function |
EP2971094B1 (en) | 2013-03-15 | 2021-09-15 | Novartis AG | Biomarkers associated with brm inhibition |
CN103243161B (zh) * | 2013-05-07 | 2015-02-25 | 中国医学科学院肿瘤医院 | 一种辅助预测食管鳞癌患者术后生存时间长短的产品 |
WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
DK3004392T3 (da) | 2013-05-30 | 2020-10-26 | Genomic Health Inc | Genekspressionsprofilalgoritme til beregning af en recidivscore for en patient med nyrecancer |
WO2015020122A1 (ja) * | 2013-08-08 | 2015-02-12 | 国立大学法人 大阪大学 | 尿路上皮癌の診断または治療剤 |
AU2014312211A1 (en) | 2013-08-28 | 2016-03-10 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP2843415B1 (en) * | 2013-08-30 | 2020-04-01 | LURIC Datenbank GbR | Methods for cardiovascular risk assessment in diabetes patients |
FR3010188B1 (fr) * | 2013-09-05 | 2017-11-24 | Univ Joseph Fourier - Grenoble 1 | Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques |
WO2015057806A1 (en) * | 2013-10-15 | 2015-04-23 | The Board Of Trustees Of The University Of Illinois | Serum mirnas for the prognosis of prostate cancer |
US10139402B2 (en) | 2013-11-06 | 2018-11-27 | Jsr Corporation | Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition |
AU2015229270B2 (en) | 2014-03-12 | 2020-12-24 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
US10801071B2 (en) | 2014-04-22 | 2020-10-13 | The Johns Hopkins University | TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors |
CN107075568A (zh) * | 2014-05-01 | 2017-08-18 | 阿姆斯特丹自由大学医学中心基金会 | 作为生物标记物的小ncRNA |
CN106714781B (zh) * | 2014-05-18 | 2021-08-10 | 儿童医学中心公司 | 涉及外排体的方法和组合物 |
US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
RU2017101174A (ru) | 2014-06-18 | 2018-07-18 | Торэй Индастриз, Инк. | Набор или устройство для обнаружения рака печени и способ обнаружения |
US11572587B2 (en) | 2014-06-26 | 2023-02-07 | Icahn School Of Medicine At Mount Sinai | Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets |
US10465183B2 (en) * | 2014-07-09 | 2019-11-05 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
WO2016021673A1 (ja) * | 2014-08-06 | 2016-02-11 | 協和発酵キリン株式会社 | small RNA含有医薬組成物の薬効を予測する方法 |
AU2015305570C1 (en) * | 2014-08-19 | 2020-07-23 | President And Fellows Of Harvard College | RNA-guided systems for probing and mapping of nucleic acids |
EP3194979B1 (en) * | 2014-09-17 | 2021-12-22 | Wallac OY | Method for determining the risk of preterm birth |
CN116731958A (zh) | 2014-10-09 | 2023-09-12 | 细胞结构公司 | 胎盘来源的贴壁细胞外泌体及其用途 |
WO2016065204A1 (en) * | 2014-10-22 | 2016-04-28 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Blood biomarkers for appendicitis and diagnostics methods using biomarkers |
WO2016081699A1 (en) * | 2014-11-19 | 2016-05-26 | Boyer Thomas G | Novel peptide activator of cyclin c-dependent kinase 8 (cdk8) |
AU2015360420B2 (en) * | 2014-12-11 | 2021-12-09 | Wisconsin Alumni Research Foundation | Methods for detection and treatment of colorectal cancer |
CN105988007A (zh) * | 2015-02-10 | 2016-10-05 | 张曼 | 尿液载脂蛋白c-ii的应用 |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3865139B1 (en) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
WO2016135168A1 (en) | 2015-02-24 | 2016-09-01 | Ruprecht-Karls-Universität Heidelberg | Biomarker panel for the detection of cancer |
WO2016145128A1 (en) | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
AU2016228748B2 (en) * | 2015-03-11 | 2021-08-19 | The General Hospital Corporation | Plasmonic nanoparticle immunoassay method |
EP3270984A4 (en) * | 2015-03-16 | 2019-04-17 | Duncan Ross | TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE |
ES2844799T3 (es) | 2015-04-17 | 2021-07-22 | Merck Sharp & Dohme | Biomarcadores sanguíneos de sensibilidad tumoral a antagonistas de PD-1 |
AU2016250570B2 (en) | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
US11525161B2 (en) | 2015-05-11 | 2022-12-13 | The Regents Of The University Of California | Methods of distinguishing ischemic stroke from intracerebral hemorrhage |
CN104887694B (zh) * | 2015-05-27 | 2018-08-24 | 中国科学院微生物研究所 | 一种靶向非编码rna的反义寡核苷酸及其在制备抗流感病毒药物中的应用 |
WO2016198749A1 (en) * | 2015-06-12 | 2016-12-15 | Turun Yliopisto | Diagnostic biomarkers, clinical variables, and techniques for selecting and using them |
CA2991045A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides binding c1q |
KR20170013621A (ko) * | 2015-07-28 | 2017-02-07 | (주) 넥셀 | Milk fat globule-EGF factor(MFG-E8)을 이용한 조직섬유화 예방 또는 치료용 조성물 |
WO2017019918A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
CN106405096A (zh) * | 2015-07-31 | 2017-02-15 | 复旦大学附属华山医院 | 核仁素在制备胃癌诊断试剂和治疗药物中的应用 |
KR101819795B1 (ko) | 2015-07-31 | 2018-01-18 | 가톨릭대학교 산학협력단 | 대장암 발병 진단 및 예측용 유전 마커 |
JP6857185B2 (ja) * | 2015-09-11 | 2021-04-14 | アプタマー サイエンス インコーポレイテッドAptamer Sciences Inc. | 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法 |
WO2017053915A1 (en) * | 2015-09-24 | 2017-03-30 | Caris Science, Inc. | Method, apparatus, and computer program product for analyzing biological data |
DK3356558T3 (da) | 2015-09-30 | 2022-04-25 | Immunexpress Pty Ltd | Sirs patogenbiomarkører og anvendelser deraf |
CN106636308B (zh) * | 2015-10-30 | 2021-03-02 | 益善生物技术股份有限公司 | 一种检测皮肤癌相关标志物的探针组合及其试剂盒 |
EP3371324B1 (en) * | 2015-11-06 | 2021-08-18 | ImmuneXpress Pty Ltd | Viral biomarkers and uses therefor |
CN105288660B (zh) * | 2015-11-19 | 2018-08-14 | 中国人民解放军第三军医大学 | MiRNA-22在制备MMP14和Snail表达抑制剂中的应用 |
JP2019505815A (ja) | 2015-12-04 | 2019-02-28 | エヌエックス・プリネイタル・インコーポレイテッドNX Prenatal Inc. | 自然早産リスクを層別化するための循環マイクロ粒子の使用 |
WO2017100620A1 (en) * | 2015-12-11 | 2017-06-15 | Sanford Health | Reagents and methods for monitoring breast cancer therapy |
EP3387430A4 (en) * | 2015-12-11 | 2019-08-14 | Expression Pathology, Inc. | SRM / MRM DOSINGS |
CN105483246B (zh) * | 2015-12-29 | 2019-01-22 | 北京泱深生物信息技术有限公司 | 基因的差异表达在口腔癌诊断中的应用 |
AU2017219415B2 (en) | 2016-02-18 | 2023-08-10 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
EP3427066A4 (en) * | 2016-03-10 | 2020-02-19 | Agency for Science, Technology and Research | LIPID BIOMARKERS FOR CANCER DIAGNOSIS |
KR20190008843A (ko) | 2016-03-18 | 2019-01-25 | 카리스 싸이언스, 인코포레이티드 | 올리고뉴클레오티드 프로브 및 이의 용도 |
CN105713985B (zh) * | 2016-04-22 | 2019-08-02 | 湖北工业大学 | 一种用于叉头转录因子o1基因突变检测的试剂及应用 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
CN105925686B (zh) * | 2016-05-12 | 2019-08-09 | 首都医科大学附属北京胸科医院 | 用于辅助检测非小细胞肺癌的标记物、引物以及检测方法 |
US11293017B2 (en) | 2016-05-25 | 2022-04-05 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
WO2017210662A1 (en) * | 2016-06-03 | 2017-12-07 | Castle Biosciences, Inc. | Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma |
GB201615330D0 (en) * | 2016-09-09 | 2016-10-26 | Univ Of Birmingham The | Method of diagnosis |
WO2018053228A1 (en) * | 2016-09-15 | 2018-03-22 | The Regents Of The University Of California | Biomarkers for bipolar disorder and schizophrenia |
US20190310258A1 (en) * | 2016-10-28 | 2019-10-10 | Japanese Foundation For Cancer Research | Biomarker, method for searching disease-related gene, and renal cancer marker |
CN108070645A (zh) * | 2016-11-11 | 2018-05-25 | 中国科学院上海生命科学研究院 | Stx-t在预防和/或治疗贫血或其相关疾病的应用 |
CN106706925B (zh) * | 2016-12-12 | 2018-08-10 | 北京大学人民医院 | 一种筛查或辅助诊断炎症性肠病的方法及适用于该方法的试剂盒 |
CN106755406A (zh) * | 2016-12-22 | 2017-05-31 | 亚能生物技术(深圳)有限公司 | 一种卵巢癌检测产品及试剂盒 |
US20200270702A1 (en) * | 2016-12-23 | 2020-08-27 | Trustees Of Boston University | Classification of diffuse large b-cell lymphoma |
WO2018151601A1 (en) * | 2017-02-17 | 2018-08-23 | Stichting Vumc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
CN107099584A (zh) * | 2017-04-06 | 2017-08-29 | 哈尔滨医科大学 | 一种与结直肠癌转移及预后相关的分子标记物及其应用 |
CN110678754A (zh) * | 2017-05-24 | 2020-01-10 | 皇家飞利浦有限公司 | 基于唾液白介素-1β以及肝细胞生长因子的牙龈炎的诊断 |
JP7034183B2 (ja) | 2017-06-13 | 2022-03-11 | ボストンジーン コーポレイション | 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法 |
KR102120659B1 (ko) * | 2017-07-06 | 2020-06-11 | 중앙대학교 산학협력단 | 난소과립막세포암 또는 자궁내막암의 진단 및 치료를 위한 마이크로rna-1236의 용도 |
CN107582525A (zh) * | 2017-08-31 | 2018-01-16 | 孙诚谊 | Trim31抑制剂磁性靶向载药微球在制备抑制pdac增殖能力药物中的应用 |
CN107400728A (zh) * | 2017-09-21 | 2017-11-28 | 西安医学院 | miR‑155作为分子标记物在诊断子痫前期中的应用 |
CN107658029A (zh) * | 2017-09-29 | 2018-02-02 | 杭州电子科技大学 | 一种全新的分布式和私有化miRNA‑疾病联系预测方法 |
CN111788487A (zh) * | 2017-12-22 | 2020-10-16 | 坦佩雷大学注册基金会 | 用于治疗眼病的预测性生物标记物 |
CN108085316B (zh) * | 2017-12-25 | 2021-02-09 | 中国人民解放军第四军医大学 | 一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法 |
CN107937621A (zh) * | 2018-01-12 | 2018-04-20 | 南方医科大学皮肤病医院(广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心) | miRNA的应用、应用其的产品及检测方法 |
CN108410987B (zh) * | 2018-03-12 | 2023-05-02 | 常州市第一人民医院 | 一种肿瘤的生物标志物及其检测方法 |
BR112020019972A2 (pt) | 2018-04-16 | 2021-01-05 | Icahn School Of Medicine At Mount Sinai | Métodos para identificar um receptor de aloenxerto renal e para identificar um receptor de aloenxerto renal em risco de rejeição aguda do aloenxerto antes do transplante, kit para identificar receptores de aloenxerto renal e método para selecionar um paciente com aloenxerto renal |
WO2019201277A1 (en) * | 2018-04-17 | 2019-10-24 | Wang Mong Lien | Method for blocking stress-induced tumor progression |
CN110408694A (zh) * | 2018-04-26 | 2019-11-05 | 胤安国际(辽宁)基因科技股份有限公司 | 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法 |
US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
CN108559778B (zh) * | 2018-04-28 | 2020-06-12 | 北京师范大学 | 多发性骨髓瘤分子分型及其在用药指导上的应用 |
CN110499251A (zh) * | 2018-05-17 | 2019-11-26 | 中国科学院大连化学物理研究所 | 高通量多参数的单细胞源性细胞外囊泡分析芯片及应用 |
TWI805777B (zh) * | 2018-06-08 | 2023-06-21 | 中央研究院 | 預測前列腺癌惡化之生物標記 |
CN108796084A (zh) * | 2018-06-27 | 2018-11-13 | 深圳天烁生物科技有限公司 | 一种卵巢癌检测试剂盒及检测方法 |
CN109055556A (zh) * | 2018-08-27 | 2018-12-21 | 中山大学 | 一种用于诊断肺癌转移的lncRNA检测试剂盒及其应用 |
CN109100496B (zh) * | 2018-08-28 | 2021-07-20 | 东华大学 | 一种织物对皮肤湿敏感性影响的评价方法 |
CN110872628A (zh) * | 2018-08-30 | 2020-03-10 | 杨昆德 | 胞外囊泡作为生物标记以制备试剂盒的用途 |
AU2019333926A1 (en) * | 2018-09-06 | 2021-04-29 | The Council Of The Queensland Institute Of Medical Research | Biomarkers for cancer therapy |
CN109022586B (zh) * | 2018-09-11 | 2022-11-29 | 朱伟 | 一种与宫颈癌辅助诊断相关的血浆miRNA标志物及其应用 |
CN109507425A (zh) * | 2018-11-07 | 2019-03-22 | 国家纳米科学中心 | 基于热泳细胞外囊泡的前列腺癌症复发监控系统及方法 |
CN109486817A (zh) * | 2018-11-13 | 2019-03-19 | 南京医科大学第二附属医院 | 一种长链非编码rna及其组合物在诊断治疗胆管癌中的应用 |
US20200174016A1 (en) * | 2018-11-30 | 2020-06-04 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Myb-related transcription factor (mypop) as diagnostic marker and therapeutic target for tumor therapy |
EP3670659A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
TWI758670B (zh) * | 2018-12-24 | 2022-03-21 | 奎克生技光電股份有限公司 | 健康風險評估方法 |
CN109998481B (zh) * | 2019-02-01 | 2024-01-30 | 中国科学院苏州生物医学工程技术研究所 | 基于光电倍增管的微弱光检测装置 |
EP3709023B1 (en) * | 2019-03-15 | 2022-03-16 | Kuen-Der Yang | Devices and methods for isolating matters of interest |
JP7343868B2 (ja) * | 2019-03-19 | 2023-09-13 | 国立大学法人愛媛大学 | 癌の予防及び/又は治療薬、癌マーカー、癌診断キット、又は生体試料の測定方法 |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
KR102203850B1 (ko) * | 2019-04-09 | 2021-01-18 | 사회복지법인 삼성생명공익재단 | 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법 |
CN111909999B (zh) * | 2019-05-07 | 2023-03-07 | 上海交通大学医学院附属瑞金医院 | miRNA组合及其在制备DLBCL预后的标记物中的应用 |
EP3973533A1 (en) * | 2019-05-22 | 2022-03-30 | Biomerieux | Methods and systems for manufacturing a production assay reactor |
CN110384796A (zh) * | 2019-07-11 | 2019-10-29 | 南京医科大学 | 马铃薯样磷脂酶7的应用 |
US20220326241A1 (en) * | 2019-08-12 | 2022-10-13 | Baylor College Of Medicine | Proteogenomic methods for diagnosing cancer |
CN112535726B (zh) * | 2019-09-05 | 2023-09-12 | 南京安吉生物科技有限公司 | 一种肿瘤标志物aquaporin 2蛋白及其应用 |
CN110609078B (zh) * | 2019-09-20 | 2022-03-11 | 南京谱利健生物技术有限公司 | 一种检测蛋白磷酸化和乙酰氨基葡萄糖化关联作用的方法 |
WO2021057986A1 (zh) * | 2019-09-27 | 2021-04-01 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备卵巢病变筛查试剂盒中的用途 |
CN110568449B (zh) * | 2019-10-14 | 2021-04-16 | 自然资源部第二海洋研究所 | 一种风生粗糙海面激光反射、透射矩阵计算方法 |
US20230005576A1 (en) * | 2019-12-05 | 2023-01-05 | Multiplai Health Ltd. | Analysis of selectively normalized spatial representations of data |
CN110749734A (zh) * | 2019-12-06 | 2020-02-04 | 四川大学华西医院 | Gtf2i自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
BR112022011328A2 (pt) * | 2019-12-09 | 2022-08-23 | Beth Israel Deaconess Medical Ct Inc | Método para determinar o risco de um evento trombótico em um paciente com câncer, método para diagnosticar e tratar uma condição trombótica em um paciente com câncer, método para monitorar o risco de uma condição trombótica em um paciente com câncer em tratamento, kit, método para examinar ppia, pdia3 e pelo menos um dentre eif5a, eif4h, eif4a3, ube2n, ube2l3, ube2i e hsp70 em uma amostra de soro ou plasma e método para examinar uma combinação de marcadores em uma amostra de fluido biológico obtida de um indivíduo humano |
WO2021132245A1 (ja) * | 2019-12-27 | 2021-07-01 | 富士フイルム和光純薬株式会社 | 転移性去勢抵抗性前立腺癌の診断を補助する方法 |
CN113940999B (zh) * | 2020-07-15 | 2022-11-29 | 中国农业大学 | 一种治疗非酒精性脂肪肝性肝病治疗靶点的应用 |
GB2613481A (en) * | 2020-07-31 | 2023-06-07 | Univ Leland Stanford Junior | Combination therapy for cancer |
CN111763716B (zh) * | 2020-08-11 | 2022-08-23 | 河南省畜牧总站 | 黄牛mogat1基因snp标记辅助选择生长性状的方法及应用 |
GB202014819D0 (en) * | 2020-08-24 | 2020-11-04 | Imperial College Innovations Ltd | A method for determining a diagnostic outcome |
CN112063725B (zh) * | 2020-09-14 | 2021-07-20 | 华南农业大学 | 鸡胫长和胫直径相关的ago3基因分子标记及应用 |
CN112501304A (zh) * | 2020-12-17 | 2021-03-16 | 浙江清华长三角研究院 | miRNA-424作为脑垂体瘤诊断标志物的应用 |
US20240052422A1 (en) | 2020-12-24 | 2024-02-15 | Pontificia Universidad Catolica De Chile | In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method |
CN112666047B (zh) * | 2021-01-14 | 2022-04-29 | 新疆大学 | 一种液体粘度检测方法 |
CN112904028B (zh) * | 2021-01-21 | 2023-11-24 | 宁波职业技术学院 | 一种血清淀粉样蛋白a质控品及其制备方法 |
CN112646895A (zh) * | 2021-01-22 | 2021-04-13 | 深圳科诺医学检验实验室 | 检测基因表达量的引物、探针、试剂盒、检测方法及应用 |
KR102632724B1 (ko) * | 2021-03-02 | 2024-02-05 | 인하대학교 산학협력단 | 췌장암의 전이 예측 또는 치료용 조성물 |
CN113265463B (zh) * | 2021-04-15 | 2023-02-28 | 山西医科大学 | Fam84b在制备食管鳞癌预后评估试剂以及在靶向治疗食管鳞癌药物的筛选中的应用 |
WO2022251655A1 (en) * | 2021-05-28 | 2022-12-01 | Guardant Health, Inc. | Compositions and methods for assaying circulating molecules |
EP4124661A1 (en) * | 2021-07-26 | 2023-02-01 | Koninklijke Philips N.V. | Personalization in prostate cancer by use of the prostate cancer pde4d7 knock-down score |
RU2766774C1 (ru) * | 2021-07-28 | 2022-03-15 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Малоинвазивный способ диагностики метастатического поражения регионарных лимфатических узлов у больных раком шейки матки на основании показателя копийности генов CCND1 и PPARGC1A |
CN113462782A (zh) * | 2021-07-30 | 2021-10-01 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 鼻咽癌标志物及其应用 |
CN117741161A (zh) * | 2021-08-30 | 2024-03-22 | 河南中医药大学 | Plekho2和npm3自身抗体在制备检测桥本甲状腺炎阴虚火旺证试剂盒中的应用 |
CN114196763B (zh) * | 2021-12-14 | 2023-05-12 | 安徽农业大学 | 一种鸭剩余采食量相关的microRNA分子标记及其应用 |
WO2023152133A1 (en) * | 2022-02-08 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing colorectal cancer |
CN114672572B (zh) * | 2022-03-14 | 2023-05-02 | 上海市农业科学院 | 一种与肉鹅10周龄体重相关的分子标记及其应用 |
CN114381529B (zh) * | 2022-03-16 | 2022-06-10 | 上海晟燃生物科技有限公司 | Actr10与ca125联合在卵巢癌检测中的应用和试剂盒 |
CN116555432B (zh) * | 2023-07-05 | 2023-09-05 | 广州凯普医药科技有限公司 | 一种膀胱癌快速检测试剂盒 |
CN117462521B (zh) * | 2023-12-28 | 2024-04-05 | 成都金瑞基业生物科技有限公司 | 和厚朴酚在制备治疗脊索瘤药物中的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2008070301A2 (en) * | 2006-10-20 | 2008-06-12 | Washington University In St. Louis | Predicting lung cancer survival using gene expression |
JP2010522554A (ja) * | 2007-03-27 | 2010-07-08 | ロゼッタ ゲノミックス エルティーディー. | 癌の分類のための遺伝子発現サイン |
JP5349838B2 (ja) * | 2007-11-30 | 2013-11-20 | 和光純薬工業株式会社 | smallRNAの取得用担体、取得方法及び取得用試薬 |
ES2600165T3 (es) * | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
US8399206B2 (en) * | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
WO2010062706A2 (en) * | 2008-10-30 | 2010-06-03 | Caris Mpi, Inc. | Methods for assessing rna patterns |
EP2730662A1 (en) * | 2008-11-12 | 2014-05-14 | Caris Life Sciences Luxembourg Holdings | Methods and systems of using exosomes for determining phenotypes |
US8815586B2 (en) * | 2009-04-24 | 2014-08-26 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions |
-
2012
- 2012-06-14 BR BR112013032232A patent/BR112013032232A2/pt not_active IP Right Cessation
- 2012-06-14 AU AU2012271516A patent/AU2012271516A1/en not_active Abandoned
- 2012-06-14 CA CA2839530A patent/CA2839530A1/en not_active Abandoned
- 2012-06-14 WO PCT/US2012/042519 patent/WO2012174282A2/en active Application Filing
- 2012-06-14 KR KR1020147001184A patent/KR20140072014A/ko not_active Application Discontinuation
- 2012-06-14 JP JP2014516002A patent/JP2014519340A/ja active Pending
- 2012-06-14 CN CN201280039945.3A patent/CN103797131A/zh active Pending
- 2012-06-14 EP EP12800642.6A patent/EP2721179A4/en not_active Withdrawn
- 2012-07-14 US US14/125,937 patent/US20140220580A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140220580A1 (en) | 2014-08-07 |
EP2721179A2 (en) | 2014-04-23 |
WO2012174282A2 (en) | 2012-12-20 |
CN103797131A (zh) | 2014-05-14 |
KR20140072014A (ko) | 2014-06-12 |
EP2721179A4 (en) | 2014-10-01 |
JP2014519340A (ja) | 2014-08-14 |
AU2012271516A1 (en) | 2014-01-23 |
CA2839530A1 (en) | 2012-12-20 |
WO2012174282A3 (en) | 2013-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013032232A2 (pt) | método de caracterização de câncer através do uso de biomarcador de ácido nucleico | |
BR112014002975A2 (pt) | composições de biomarcador e métodos | |
BR112013031591A2 (pt) | biomarcadores de circulação para câncer | |
WO2013134786A3 (en) | Biomarker compositions and methods | |
BR112012025593A2 (pt) | biomarcadores em circulação para doença | |
WO2014193999A3 (en) | Biomarker methods and compositions | |
BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
WO2013022953A3 (en) | Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof | |
DE602005014148D1 (de) | Nukleinsäuren für die apoptose von krebszellen | |
EA201491399A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
WO2017027391A3 (en) | Genetic abnormalities in plasma cell dyscrasias | |
NZ706420A (en) | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | |
HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
BR112012030838A2 (pt) | molécula de ácido nucléico isolada que codifica uma proteína mek1 mutante tendo atividade de mek1, vetor de expressão, célula hospedeira, método de produzir uma prote ína mek1 mutante, proteína mek1 mutante isolada, método de identificar um paciente que tem câncer, método de orimizar o tratamento de um paciente que tem câncer,e, uso de um inibidor de raf e de um inibidor de mek. | |
BR112015023699A2 (pt) | método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo | |
WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
EP3879269A3 (en) | Methods of measuring signaling pathway activity for selection of therapeutic agents | |
WO2012040602A3 (en) | Targeting mtor substrates in treating proliferative diseases | |
WO2013071012A3 (en) | Personalized strategic cancer treatment | |
WO2016201365A3 (en) | Methods for treating cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B25D | Requested change of name of applicant approved |
Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH) |
|
B25G | Requested change of headquarter approved |
Owner name: CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |